Previous 10 | Next 10 |
2023-05-31 12:07:41 ET Summary Shares of Calliditas Therapeutics plunged after the company missed Q1 revenue estimates. The quarter was better than it looks and the company saw record new patient enrollments for Tarpeyo. It was also too early for the recently reported 2-year e...
2023-05-30 06:54:18 ET Summary Patient and Prescriber Uptick: Despite Q1 2023's slightly disappointing earnings, Tarpeyo saw robust growth in new patient enrollments and prescriber numbers. Competitive Edge: Recent Phase 3 DUPLEX FSGS readout from Travere showing non-stat signific...
2023-05-16 18:55:18 ET Summary HSCT-TMA BLA Resubmission: Omeros plans to resubmit a BLA for narsoplimab, potentially gaining approval by Q2 2024. IgAN Trial Progress: Top-line results for the phase 3 ARTEMIS trial on narsoplimab for IgAN are expected in Q3 2023. Solid Financi...
2023-05-16 10:07:34 ET Gainers: Phio Pharmaceuticals ( PHIO ) +30% . Coya Therapeutics ( COYA ) +23% . Nanobiotix ( NBTX ) +12% . Savara ( SVRA ) +12% . Bellerophon Therapeutics ( BLPH ) +11% . Losers: Eloxx Pharmaceutical...
Calliditas Therapeutics: Interim Report Q1, 2023 PR Newswire STOCKHOLM , May 16, 2023 /PRNewswire/ -- Strong eGFR Data from Positive NefIgArd Phase 3 Trial Readout "In March we announced that the global NefIgArd Phase 3 trial successfully met its prim...
2023-04-27 09:17:35 ET Summary Part B portion of Phase 3 NefIgArd trial reveals positive outcomes for nefecon, leading to a reaffirmed buy recommendation for Calliditas. Nefecon demonstrates statistically significant stabilization of eGFR levels in IgAN patients, with consistent b...
Calliditas Therapeutics' 2022 Annual Report Published PR Newswire STOCKHOLM , April 26, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) today announces that the Annual Report for 2022 now is available at the company's websi...
2023-04-12 06:34:14 ET Summary Calliditas Therapeutics recently reported positive long-term data of Tarpeyo (Nefecon/budesonide) in patients with IgA nephropathy. The results confirmed the previous positive findings from the phase 3 trial and indicate a potential disease-modifying...
NEW YORK, April 11, 2023 (GLOBE NEWSWIRE) -- Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”), announced the publication of a cost-effective analysis of Nefecon (marketed in the United States as TARPEYO® (budesonide) delayed release capsules) ...
2023-04-06 05:40:50 ET Singapore's Health Sciences Authority (HSA) accepted to review Everest Medicines' application seeking approval of Nefecon to treat primary immunoglobulin A nephropathy (IgAN) in adults at risk of disease progression. The company expects to get approval of the...
News, Short Squeeze, Breakout and More Instantly...
Calliditas Therapeutics AB Company Name:
CALT Stock Symbol:
NASDAQ Market:
Launch of Phase 3 clinical trial with Nefecon in Japan PR Newswire STOCKHOLM , July 4, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT) (STO: CALTX) ("Calliditas") today announces that its partner Viatris Pharmaceutical Japan G.K. ("Viatri...
2024-06-30 09:14:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Calliditas provides setanaxib patent update PR Newswire STOCKHOLM , June 18, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announced that the United States Patent and Trademark Office (USPTO) h...